North America Drug Screening Market Flourishes Relentlessly; Asserts MRFR Unleashing Industry Forecast Up To 2023

“North America Drug Screening Market”
Market Research Future published a half cooked research report on “North America Drug Screening Market – Forecast to 2023”-Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023.

Usually drug testing is done for patients who are unable to tell what kind of drugs they were taking in the past. This is particularly useful when the patients are suffering from serious medical conditions or are unconscious. The drug testing can be used to determine allergies caused by drugs and is also in pain management. The test samples for drug screening, are inclusive of samples like hair, saliva, blood, urine, and others. Rising number of roadside accidents due to DUI and government initiatives to curb DUI is one of the major driver for the market growth. Additionally, rise in the awareness among the population in developing countries regarding the adverse effects of drugs misuse is boosting the market growth during the forecast period.

North America drug screening market is growing with the rapid pace. According to a recent study report published by the Market Research Future, the North America drug screening market is booming and expected to gain prominence over the forecast period. The market is projected to demonstrate a spectacular growth by 2023, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period (2017 – 2023).

Get a sample report at https://www.marketresearchfuture.com/sample_request/1507 .

Siemens Medical Solutions USA, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics, Roche Diagnostics, Thermo Fisher Scientific, Inc., Express Diagnostics Int’l Inc., Shimadzu, MPD, Inc., and Alere Toxicology and others are the prominent players at the forefront of competition in the North America drug screening market and are profiled in MRFR Analysis.

North America Drug Screening Market – Competitive Analysis

Characterized by the presence of several well-established and small players, the North America drug screening market appears to be a highly competitive and fragmented market. International players who are increasingly expanding their footprint in the developing economy, making it difficult for regional vendors to compete with them, especially in terms of features product portfolios, quality, and pricing. The market is witnessing intensified competition which is expected to get more intensified further during the forecast period. The intense competition prevalent in the market dictates the consolidation among marketers.

Well established players incorporate acquisition, collaboration, partnership, expansion, and product launch in order to gain competitive advantage in this market and to maintain their market position.

In Feb-2016, Quest Diagnostics, the world’s leading provider of diagnostic information services, completed their acquisition of the outreach laboratory service business of Clinical Laboratory Partners (CLP), a wholly-owned subsidiary of Hartford HealthCare (HHC). HHC is an integrated health care system with five hospitals in Connecticut. Financial terms were not disclosed.

In June-2017, Siemens Healthineers expanded its Population Health Management (PHM) portfolio by the acquisition of Medicalis Corporation based in San Francisco and Kitchener, Ontario. Medicalis is a leading provider of Clinical Decision Support (CDS) Solutions at the point of order entry, Imaging Workflow (IW) management, and Referral Management (RM). By incorporating these offerings into its PHM portfolio, Siemens Healthineers enabled healthcare providers to effectively bridge between PHM at the health system level and at the departmental level.

In Nov-2017, Roche announced an agreement with Viewics, Inc., a privately held software company focused on laboratory business analytics. Under the agreement, Roche is acquiring all shares of the company. The acquisition, is subjected to customary closing conditions, is expected to close on November 21, 2017. This acquisition allows Roche to expand its leading position in the Integrated Core Lab with business analytics capabilities, enabling laboratories to make faster data-driven informed decisions on their operations and processes. The cloud-based solution is secure, infrastructure-agnostic, interactive, and accessible from multiple devices.

In Sep-2016, Thermo Fisher Scientific Inc., the world leader in serving science, completed their acquisition of FEI Company, Inc., the leader in high-performance electron microscopy, for $107.50 per share in cash, or a total purchase price of approximately $4.2 billion.

Browse Complete Report at https://www.marketresearchfuture.com/reports/north-america-drug-screening-market-1507 .

North America Drug Screening Market – Regional Analysis

The North America provide favourable conditions for the growth of the market during the forecast period. Regionally, North America is divided into the U.S. and Canada. Presence of the developed healthcare services, increasing awareness along with the rising incidences of the drug abuse by the teenagers makes the U.S. a major contributor to the market growth. On the other hand Canada is estimated to be the fastest growing region during the forecast period, 2017-2023.

Media Contact
Company Name: Market Research Future
Contact Person: Akash Anand
Email: akash.anand@marketresearchfuture.com
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune –
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/north-america-drug-screening-market-1507